DaVita Inc. is an American company that provides kidney dialysis services through a network of 2,675 outpatient centers in the United States, serving 200,800 patients, and 367 outpatient centers in 11 other countries serving 49,400 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo kidney dialysis, often 3 times per week for the rest of their lives unless they receive a kidney transplant via organ donation. The company has a 37% market share in the U.S. dialysis market. It is incorporated in Delaware and headquartered in Denver.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| DVA | DAVITA INC. | 2026-02-18 04:46:10 | 150.39 | 0.04 | 0.03 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DVA | 0000927066 | DAVITA INC. | US23918K1088 | M2XHYMU3TZNEZURC6H66 | 510354549 | NYSE | 8090 | Services-Misc Health & Allied Services, NEC | 1231 | DE | 2000 16TH STREET | DENVER | CO | 80202 | UNITED STATES | US | 310-536-2668 | 2000 16TH STREET, DENVER, CO, 80202 | 2000 16TH STREET, DENVER, CO, 80202 | DAVITA HEALTHCARE PARTNERS INC. | Healthcare | 1992 | Javier J. Rodriguez | 76,000 | https://davita.com | 10,600,000,000 | 68,549,000 | 66,800,000 | DaVita Inc. is an American company that provides kidney dialysis services through a network of 2,675 outpatient centers in the United States, serving 200,800 patients, and 367 outpatient centers in 11 other countries serving 49,400 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo kidney dialysis, often 3 times per week for the rest of their lives unless they receive a kidney transplant via organ donation. The company has a 37% market share in the U.S. dialysis market. It is incorporated in Delaware and headquartered in Denver. | 2026-02-12 16:12:24 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 10,600,000,000 | -1,200,000,000 | -10.1695 | 66,800,000 | -13,200,000 | -16.5 |
| 2024 | 11,800,000,000 | 2,600,000,000 | 28.2609 | 80,000,000 | -7,700,000 | -8.7799 |
| 2023 | 9,200,000,000 | 1,800,000,000 | 24.3243 | 87,700,000 | -2,700,000 | -2.9867 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| James O. Hearty | Chief Compliance Officer | 2024 | 569,231 | 0 | 932,104 | 831,724 | 3,840 | 2,336,899 |
| Javier J. Rodriguez | Chief Executive Officer | 2024 | 1,500,000 | 0 | 15,849,833 | 4,118,119 | 339,537 | 21,807,489 |
| Joel Ackerman | Chief Financial Officer, Treasurer | 2024 | 769,231 | 0 | 4,112,322 | 1,464,220 | 3,840 | 6,349,613 |
| David P. Maughan | Chief Operating Officer | 2024 | 615,385 | 0 | 3,000,014 | 1,313,899 | 3,840 | 4,933,138 |
| Michael D. Staffieri | Chief Operating Officer | 2024 | 800,000 | 0 | 4,934,939 | 2,174,730 | 393,643 | 8,303,312 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 13,643,069,000 | 12,815,550,000 | 12,140,147,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | — | — | — |
| General And Administrative Expenses | 1,673,630,000 | 1,538,341,000 | 1,473,984,000 |
| Operating Expenses | 11,599,454,000 | 10,725,067,000 | 10,537,363,000 |
| Operating Income | 2,043,615,000 | 2,090,483,000 | 1,602,784,000 |
| Net Income | 746,803,000 | 936,342,000 | 691,535,000 |
| Earnings Per Share Basic | 10.06 | 11.02 | 7.62 |
| Earnings Per Share Diluted | 9.84 | 10.73 | 7.42 |
| Weighted Average Shares Outstanding Basic | 74,227,000 | 84,991,000 | 90,790,000 |
| Weighted Average Shares Outstanding Diluted | 75,885,000 | 87,274,000 | 93,182,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 676,438,000 | 794,933,000 | 380,063,000 |
| Marketable Securities Current | 24,303,000 | 51,064,000 | 11,610,000 |
| Accounts Receivable | 2,414,690,000 | 2,146,975,000 | 1,986,856,000 |
| Inventories | 160,627,000 | 134,559,000 | 143,105,000 |
| Non Trade Receivables | 49,937,000 | 27,535,000 | 6,387,000 |
| Other Assets Current | 91,717,000 | 83,038,000 | 74,337,000 |
| Total Assets Current | 4,058,003,000 | 3,746,072,000 | 3,137,906,000 |
| Marketable Securities Non Current | 40,966,000 | 33,660,000 | 47,890,000 |
| Property Plant And Equipment | 2,812,966,000 | 2,940,916,000 | 3,073,533,000 |
| Other Assets Non Current | 246,520,000 | 261,731,000 | 271,253,000 |
| Total Assets Non Current | 13,422,100,000 | 13,539,196,000 | 13,755,672,000 |
| Total Assets | 17,480,103,000 | 17,285,268,000 | 16,893,578,000 |
| Accounts Payable | 696,148,000 | 547,200,000 | 514,533,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 109,201,000 | 270,867,000 | 123,299,000 |
| Other Liabilities Current | 893,024,000 | 934,145,000 | 828,878,000 |
| Total Liabilities Current | 3,141,634,000 | 2,973,410,000 | 2,642,214,000 |
| Long Term Debt | 10,163,988,000 | 9,175,903,000 | 8,268,334,000 |
| Other Liabilities Non Current | 83,516,000 | 169,588,000 | 183,074,000 |
| Total Liabilities Non Current | 13,180,031,000 | 12,220,507,000 | 11,508,014,000 |
| Total Liabilities | 16,321,665,000 | 15,193,917,000 | 14,150,228,000 |
| Common Stock | 69,000 | 90,000 | 89,000 |
| Retained Earnings | -328,428,000 | 1,534,630,000 | 598,288,000 |
| Accumulated Other Comprehensive Income | -122,783,000 | -310,796,000 | -52,084,000 |
| Total Shareholders Equity | -651,082,000 | 121,122,000 | 1,056,097,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 715,348,000 | 723,860,000 | 745,443,000 |
| Share Based Compensation Expense | 139,953,000 | 102,788,000 | 112,375,000 |
| Other Non Cash Income Expense | 17,549,000 | -13,414,000 | 8,938,000 |
| Change In Accounts Receivable | 210,632,000 | 29,766,000 | -172,361,000 |
| Change In Inventories | 19,950,000 | -17,942,000 | 32,132,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 128,303,000 | 1,699,000 | 26,890,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 1,886,500,000 | 2,022,038,000 | 2,059,031,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 575,864,000 | 555,443,000 | 567,985,000 |
| Acquisition Of Business | 117,468,000 | 246,068,000 | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -654,949,000 | -771,429,000 | -771,800,000 |
| Tax Withholding For Share Based Compensation | 35,291,000 | 134,040,000 | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 1,308,366,000 | 1,385,932,000 | 272,219,000 |
| Issuance Of Long Term Debt | 5,612,280,000 | 6,624,310,000 | 2,468,341,000 |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -1,374,780,000 | -816,937,000 | -1,170,495,000 |
| Change In Cash | -122,078,000 | 415,191,000 | 125,645,000 |
| Cash At End Of Period | 676,438,000 | 794,933,000 | 380,063,000 |
| Income Taxes Paid | 176,688,000 | 387,940,000 | 268,091,000 |
| Interest Paid | 515,497,000 | 423,360,000 | 387,661,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 10.06 | 11.02 | 7.62 |
| Price To Earnings Ratio | 11.2932 | 13.5708 | 13.748 |
| Earnings Growth Rate | -8.7114 | 44.6194 | 26.3682 |
| Price Earnings To Growth Ratio | -1.2964 | 0.3041 | 0.5214 |
| Book Value Per Share | 15.6067 | 24.6067 | 30.2164 |
| Price To Book Ratio | 7.2796 | 6.0776 | 3.467 |
| Ebitda | 2,178,763,000 | 2,483,345,000 | 2,079,020,000 |
| Enterprise Value | 18,029,680,470 | 21,362,241,050 | 17,522,730,400 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | -15.7786 | 77.9938 | 7.9459 |
| Capital Expenditures | 587,398,000 | 591,243,000 | 562,579,000 |
| Free Cash Flow | 1,299,102,000 | 1,430,795,000 | 1,496,452,000 |
| Return On Equity | -1.147 | 7.7306 | 0.6548 |
| One Year Beta | 0.476 | 0.4622 | 0.7541 |
| Three Year Beta | 0.5382 | 0.5206 | 0.5297 |
| Five Year Beta | 0.5073 | 0.6862 | 0.7183 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| ACKERMAN JOEL | CFO and Treasuer | 2026-02-06 | 44,065 | A | 185,705 |
| ACKERMAN JOEL | CFO and Treasuer | 2026-02-06 | 32,168 | D | 153,537 |
| ACKERMAN JOEL | CFO and Treasuer | 2026-02-06 | 5,100 | D | 148,437 |
| ACKERMAN JOEL | CFO and Treasuer | 2026-02-06 | 44,065 | D | 0 |
| Waters Kathleen Alyce | Chief Legal & Pub. Affairs Off | 2026-02-06 | 8,079 | A | 105,833 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Jerry Moran | Senator | 2024-01-17 | Sale (Full) | 2023-12-14 | Spouse | $1,001 - $15,000 |
| Jerry Moran | Senator | 2024-01-17 | Sale (Full) | 2023-12-14 | Self | $1,001 - $15,000 |
| Thomas H Tuberville | Senator | 2024-01-12 | Sale (Full) | 2023-12-12 | Joint | $1,001 - $15,000 |
| Thomas H Tuberville | Senator | 2023-07-14 | Sale (Partial) | 2023-06-12 | Joint | $1,001 - $15,000 |
| Jerry Moran | Senator | 2022-01-21 | Sale (Partial) | 2021-12-21 | Self | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Julie Johnson | 2025-10-07 | TX32 | Sale | 2025-09-25 | Joint | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| MACKENZIE FINANCIAL CORP | 2025-12-31 | 1,012,595 | 8,914 | 113.596 |
| MERCER GLOBAL ADVISORS INC /ADV | 2025-12-31 | 1,729,155 | 15,220 | 113.6107 |
| RAYMOND JAMES FINANCIAL INC | 2025-12-31 | 2,985,103 | 26,275 | 113.61 |
| Cetera Investment Advisers | 2025-12-31 | 852,983 | 7,508 | 113.6099 |
| Freestone Grove Partners LP | 2025-12-31 | 836,170 | 7,360 | 113.6101 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| EMPOWER FUNDS, INC. | 2025-12-31 | Institutional Class | MXKWX | 5,992 | 680,751.13 | 0.0074 |
| EMPOWER FUNDS, INC. | 2025-12-31 | Investor Class | MXVIX | 5,992 | 680,751.13 | 0.0074 |
| EMPOWER FUNDS, INC. | 2025-12-31 | Institutional Class | MXFRX | 255,000 | 264,407.69 | 0.033 |
| EMPOWER FUNDS, INC. | 2025-12-31 | Institutional Class | MXFRX | 4,440,000 | 4,621,889.11 | 0.5761 |
| EMPOWER FUNDS, INC. | 2025-12-31 | Investor Class | MXHYX | 255,000 | 264,407.69 | 0.033 |